EU Suspends Deadline For Illumina's $8B Grail Deal
European
enforcers hit the pause button on their review of DNA sequencing giant
Illumina's $8 billion reacquisition of cancer detection outfit Grail, a deal
already being challenged by the Federal Trade Commission in the U.S.
No comments:
Post a Comment